Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: Results from the Swiss SCQM registry - 30/05/13
, Jean Dudler b, Almut Scherer c, Axel Finckh d
Corresponding author. Tel.: +41 21 31 41 522; fax: +41 21 31 41 533.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 5 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objective |
In Switzerland, the prescription of biologic antirheumatic agents in rheumatoid arthritis (RA) patients is not limited by stringent requirements from health authorities. The goals of this study were to: determine the characteristics of the Swiss patients at the initiation of biologics, compare them with other countries and evaluate whether different disease activity levels at initiation of therapy, resulting from distinct access to these treatment, influence their effectiveness.
Methods |
This is a retrospective cohort study of RA patients followed in the Swiss register (SCQM-RA). Two thousand and sixty patients treated with biologics were retrieved. We present the disease characteristics and the patients’ demographic data, at initiation and some effectiveness data after 1 year of treatment.
Results |
Two thousand and sixty patients treated with biologics were retrieved. At initiation of treatment, the mean disease activity DAS (SD): 4.4 (1.4), number of previous antirheumatic treatments: 1.1, functional status HAQ: 1.1 (0.7) and median duration of illness: 5.5 years were significantly lower than in other published registries. The mean DAS: 3.3 (1.4) 1 year after initiation of therapy also appears lower than in other countries. Additionally, patients treated more recently (after 2005) had a significantly higher improvement in mean DAS.
Conclusions |
Data from the Swiss RA registry demonstrate that biologics are prescribed at a lower level of disease activity and after fewer prior DMARD failures than in most other countries, a practice that seems to correlate with overall lower absolute levels of disease activity and better patient outcomes after 1 year of treatment.
Le texte complet de cet article est disponible en PDF.Keywords : Rheumatoid arthritis, Biologic treatments, Disease activity, Epidemiologic data, Swiss patients, Registry
Plan
Vol 80 - N° 2
P. 160-164 - mars 2013 Retour au numéro
Article précédent
- Improving agreement in assessment of synovitis in rheumatoid arthritis
- Peter P. Cheung, Maxime Dougados, Vincent Andre, Nathalie Balandraud, Gérard Chales, Isabelle Chary-Valckenaere, Emmanuel Chatelus, Emmanuelle Dernis, Ghislaine Gill, Mélanie Gilson, Sandrine Guis, Gael Mouterde, Stephan Pavy, François Pouyol, Thierry Marhadour, Pascal Richette, Adeline Ruyssen-Witrand, Martin Soubrier, Laure Gossec
- Blockade of intra-articular TNF in peripheral spondyloarthritis: Its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers
- Ugo Fiocco, Paolo Sfriso, Francesca Oliviero, Francesca Lunardi, Fiorella Calabrese, Elena Scagliori, Luisella Cozzi, Antonio Di Maggio, Roberto Nardacchione, Béatrice Molena, Mara Felicetti, Katia Gazzola, Roberto Stramare, Léopoldo Rubaltelli, Benedetta Accordi, Luisa Costa, Pascale Roux-Lombard, Leonardo Punzi, Jean-Michel Dayer
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?